Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis

Charlotte J Green1,*, Thomas Marjot1,2,*, John Walsby-Tickle3, Catriona Charlton1, Thomas Cornfield1, Felix Westcott3, Katherine E Pinnick1, Ahmad Moolla1, Jonathan M Hazlehurst1,4, James McCullagh3, Jeremy W Tomlinson1,5 and Leanne Hodson1,5

1Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, UK, 2Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, UK, 3Chemistry Research Laboratory, University of Oxford, Oxford, UK, 4Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK, and 5NIHR Oxford Biomedical Research Centre, Oxford University Hospital Trusts, Oxford, UK

* (C J Green and T Marjot contributed equally to this work)  †(J W Tomlinson and L Hodson are joint senior authors)

Abstract

Objective: Metformin is a first-line pharmacotherapy in the treatment of type 2 diabetes, a condition closely associated with non-alcoholic fatty liver disease (NAFLD). Although metformin promotes weight loss and improves insulin sensitivity, its effect on intrahepatic triglyceride (IHTG) remains unclear. We investigated the effect of metformin on IHTG, hepatic de novo lipogenesis (DNL), and fatty acid (FA) oxidation in vivo in humans.

Design and methods: Metabolic investigations, using stable-isotope tracers, were performed in ten insulin-resistant, overweight/obese human participants with NAFLD who were treatment naïve before and after 12 weeks of metformin treatment. The effect of metformin on markers of s.c. adipose tissue FA metabolism and function, along with the plasma metabolome, was investigated.

Results: Twelve weeks of treatment with metformin resulted in a significant reduction in body weight and improved insulin sensitivity, but IHTG content and FA oxidation remained unchanged. Metformin treatment was associated with a significant decrease in VLDL-triglyceride (TG) concentrations and a significant increase in the relative contribution of DNL-derived FAs to VLDL-TG. There were subtle and relatively few changes in s.c. adipose tissue FA metabolism and the plasma metabolome with metformin treatment.

Conclusions: We demonstrate the mechanisms of action of metformin whereby it improves insulin sensitivity and promotes weight loss, without improvement in IHTG; these observations are partly explained through increased hepatic DNL and a lack of change in FA oxidation.

Introduction

Non-alcoholic fatty liver disease (NAFLD) (also known as metabolic associated fatty liver disease (MAFLD) (1)) affects approximately 25% of the global population (2). NAFLD is strongly associated with obesity, type 2 diabetes (T2D), and cardiovascular disease (CVD) and begins with pathological accumulation of intrahepatic triglyceride (IHTG) (steatosis) which can progress to more severe liver disease (1). The accumulation of IHTG represents an imbalance between the amount of fatty acids (FA) entering the liver, FA synthesis (de novo lipogenesis (DNL)) within the liver,
and FA disposal (via oxidation or export as triglyceride (TG) in VLDL) from the liver (3); insulin plays a key role in the regulation of these processes (3). Enhanced hepatic DNL has been suggested to contribute towards insulin resistance and NAFLD (4). Insulin resistance is often considered a hallmark of NAFLD and is the best predictor of liver disease progression (5).

In patients with T2D, it is well recognised that treatment with metformin leads to improvements in glycaemic control and insulin sensitivity. Based on observations in rodent models, metformin has been suggested as a possible candidate for the pharmacological treatment of NAFLD (6), an area of significant unmet clinical need as there is currently no licenced drug therapy, with the treatment and management of NAFLD being focussed predominantly on lifestyle and dietary modification (7). This contrasts with the multiple licenced medications available for the treatment of T2D. However, data are conflicting with the positive impact of metformin on IHTG being observed in rodent models not reliably translating into human studies (8). While rodent models have shown metformin to reduce IHTG through AMP-activated protein kinase (AMPK)-mediated FA oxidation and decreased hepatic DNL (8), meta-analyses of human trials suggest no histological benefit despite improvements in body weight and glycaemic control (9, 10). We therefore aimed to explain this disconnect by using experimental medicine and stable-isotope tracer techniques in an in vivo human study to characterise FA synthesis (DNL) and partitioning in response to metformin.

Subjects and methods

Study participants

We recruited individuals (six female and four male) who were insulin resistant ($n=8$) or who were diagnosed with T2D at the time of study enrolment ($n=2$). All participants were treatment naïve, overweight or obese, and at increased risk of NAFLD. Participants were recruited from the Oxford BioBank (OBB) (www.oxfordbiobank.org.uk) (11) and were aged between 36 and 63 years, had a BMI between 26 and 42 kg/m$^2$, were insulin resistant (defined as fasting insulin in the 90th centile of the OBB), and were not taking medications known to alter hepatic metabolism, blood glucose and lipid concentrations, or body weight. Participants were excluded if they consumed excess alcohol (females >14 units/week and males >21 units/week) or had known liver disease. The study was approved by North of Scotland Research Ethics Committee (15/NS/0117) and all subjects gave written informed consent. This physiological study was registered at www.clinicaltrials.org ID number NCT02696941. This included an assessment of sodium-glucose co-transporter 2 treatment on IHTG using similar techniques which have been published elsewhere (12). The focus of the current work was to decipher the precise mechanistic impact of metformin on IHTG and to offer explanations for the inconsistent observations in previous rodent and human studies.

Study design

We performed a single centre, open label trial for 12 weeks. Baseline investigations included measurement of IHTG by proton magnetic resonance spectroscopy ($^1$H-MRS) (13) and a two-step hyperinsulinaemic–euglycaemic clamp utilising stable-isotope methodologies (12). IHTG content measurements and metabolic assessments were performed prior to and then again after 12 weeks of treatment with metformin, after which all treatment was stopped. Metformin was initiated at 500 mg once a day and increased weekly, as tolerated, by 500 mg up to maximum dose of 1 g twice a day (Fig. 1).

Metabolic study day

For 48 h prior to the metabolic study days, participants were asked to avoid foods naturally enriched in $^{13}$C, alcohol, and strenuous exercise. The evening prior to the study day, subjects consumed deuterated water ($^2$H$_2$O) (3 g/kg body water) and continued to consume $^2$H$_2$O during the course of the two-step hyperinsulinaemic–euglycaemic clamp for the measurement of hepatic DNL as described (14). On the study day, participants came to the clinical research unit, where body composition was assessed at the start of the study using impedance.

To assess hepatic and peripheral insulin sensitivity using the two-step hyperinsulinaemic–euglycaemic clamp, we performed a single control and study day with two-step hyperinsulinaemic–euglycaemic clamp utilising stable-isotope methodologies (12). IHTG content measurements and metabolic assessments were performed prior to and then again after 12 weeks of treatment with metformin, after which all treatment was stopped. Metformin was initiated at 500 mg once a day and increased weekly, as tolerated, by 500 mg up to maximum dose of 1 g twice a day (Fig. 1).

**Figure 1**

Overview of study design. MRI/S, MRI and spectroscopy; IHTG, intrahepatic triglyceride content; ‘clamp’, two-step hyperinsulinaemic–euglycaemic clamp.
clamp, arterialisated blood was sampled to determine the blood glucose concentration to be maintained (‘clamped’) throughout the study. Steady state blood was sampled at the end of each phase and rates of hepatic endogenous glucose production (EGP) and glucose disposal were calculated using modified versions of the Steele Equations (15). Intravenous infusions of [6,6-D_{2}]glucose and [U^{13}C]palmitic acid complexed with human albumin (0.03 μmol/kg/min) (to assess the rate of appearance (Ra) of non-esterified fatty acids (NEFA), FA oxidation, and intrahepatic FA partitioning) were commenced at the start of the study day (time 0), and steady state blood samples were taken after 2 h of this basal phase and at two phases on infused insulin as described (12).

Breath samples were collected over the course of each phase in EXETAINER tubes (Labco Ltd, High Wycombe, UK) to determine $^{13}$CO$_2$ production.

### Adipose tissue biopsies

Subcutaneous abdominal adipose tissue samples were taken by needle biopsy from eight participants from the periumbilical area before and after metformin treatment and mRNA was extracted from biopsies, reverse transcribed, and qPCR assays for relevant genes undertaken (16, 17).

### Analytical procedures

Whole blood was collected into heparinized syringes and plasma rapidly separated for the measurement of plasma metabolite and insulin concentrations (18). Separations of VLDL were made by sequential flotation using density gradient ultracentrifugation and expired breath collected as described (18).

### Plasma and breath isotopic enrichment

Gas chromatography-mass spectrometry (GC-MS) was used to determine plasma glucose (19) and FA enrichment (14), and the tracer-to-tracee ratio (TTR) of a sample prior to the administration of the respective tracers was subtracted from the TTR of each sample to account for natural abundance. $^{13}$CO$_2$ production, as a marker of whole-body FA oxidation, was calculated and corrected for lean mass (determined by impedance) (20). Hepatic DNL was based on the incorporation of deuterium from $^2$H$_2$O in plasma water into VLDL-TG palmitate using GC-MS (14, 21).

### Plasma metabolomics analysis

We undertook a preliminary assessment of the plasma metabolome before and after metformin treatment. Plasma samples were collected prior to the start of infusions and metabolomics analysis was undertaken using ion chromatography- and reversed-phase-mass spectrometry (MS) methods (22) and for amino acid analysis using liquid chromatography. A 5 μL partial loop injection was used for all analyses and chromatographic separation was performed using a Dionex Ultimate 3000 UHPLC system (Thermo Scientific) coupled to a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific). The Q Exactive mass spectrometer was equipped with a heated electrospray ionisation probe in positive ion mode.

### Statistical analysis

We based our power calculations on the work of others, who found a 20–40% decrease in fasting plasma glucose concentrations with metformin treatment between 16 and 96 weeks (23, 24, 25). We recruited individuals who were in the top 20% for fasting glucose concentrations (6.5 ± 0.5 mmol/L (mean ± s.d.)) in the OBB, but without a known diagnosis of T2D. We predicted a conservative decrease of 10% in plasma glucose and with a power of 0.80 at α of 0.05 required 11 individuals. However, as we only recruited ten individuals, who achieved a 5% decrease in plasma glucose concentrations, it is likely the study was underpowered for many of the reported outcomes. Thus, we have used this physiological study as a platform to explore whether metformin affected IHTG content, hepatic DNL, and FA oxidation in humans. Data were analysed using SPSS for Windows v22 (SPSS). Areas under the curve (AUCs) were calculated by the trapezoid method. AUCs have been divided by the relevant time period to give time-averaged values. All data sets were tested for normality according to the Shapiro–Wilks test. Comparisons within the group before and after treatment with metformin were made using a Student’s paired t-test or the non-parametric equivalent. Data across the hyperinsulinaemic–euglycaemic clamp were compared using repeated measures ANOVA, with time and treatment as factors to investigate the change. Bonferroni post hoc analysis was performed where appropriate to adjust for multiple comparisons. Associations between variables were carried out using Spearman’s rank correlation coefficient. For plasma metabolomics, comparisons were made using MetaboAnalyst (26), and P-values were not corrected for multiple testing. For all analysis, statistical
Results

Anthropometric and fasting biochemical measures

Ten adults (six females and four males) completed the study (Table 1). After 12 weeks of treatment with metformin, there was a significant ($P < 0.05$) decrease in BMI, which resulted from an average decrease of 2.3 kg in body weight (range: $−6.4$ to $+1.64$kg) (Fig. 2A and Table 1), along with non-significant decreases in fat and lean masses; IHTG content remained unchanged (range: $−3.6$% to $+9.9$%) (Fig. 2B and Table 1). To ensure that the individual with the largest increase in IHTG was not driving this observation, we excluded them from the analysis and found this had no effect on the outcome. The association between change in body weight and IHTG across the study was not significant ($r_t = 0.58$, $P = 0.08$). Plasma lactate significantly ($P < 0.05$) increased and there was no change in plasma total, and HDL- and non-HDL cholesterol concentrations with metformin treatment (Table 1).

Insulin sensitivity plasma glucose and insulin

The Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) significantly ($P < 0.05$) decreased after 12 weeks treatment with metformin (Table 1); there were non-significant decreases in plasma glucose and insulin concentrations (Table 1). Over the course of the clamp, there was no change in plasma glucose concentrations (Fig. 2C), although the amount of insulin required to maintain glucose homeostasis was significantly ($P < 0.05$) lower in both the low and high insulin phases after metformin treatment (Fig. 2D). The decreased insulin may be due to metformin treatment leading to an increase in insulin clearance and/or is a reflection of the decrease in body weight, as infusion rates were calculated on a per body mass (kg) basis. There was a non-significant increase in the rate of disposal (Rd) of glucose after metformin treatment ($9.7 ± 1.0$ (pre) vs $12.3 ± 1.9$ (post) $\mu$mol/min/kg) in the basal state. Rd glucose then significantly ($P < 0.01$) increased between the low and high insulin clamp phases with no effect of treatment (Fig. 2E). In the basal phase, Ra glucose increased significantly ($P < 0.05$) post-metformin when compared to pre-metformin treatment (Fig. 2F). Between the basal and low insulin phase, Ra glucose significantly decreased post-metformin test but not pre-metformin treatment (Fig. 2F).

Adipose tissue FA metabolism

Metformin treatment had little effect on plasma NEFA concentrations either in the basal state or during the study day, with the expected suppression occurring over

Table 1  Participant characteristics and plasma biochemical parameters pre and post 12 weeks of treatment with metformin. Data are presented as mean ± S.E.M.

|                  | Pre-metformin | Post-metformin |
|------------------|---------------|----------------|
| BMI (kg/m²)      | 33.5 ± 1.3    | 32.7 ± 1.4*    |
| Body weight (kg) | 93.4 ± 5.9    | 91.1 ± 5.9*    |
| IHTG (%)         | 15.9 ± 3.7    | 17.1 ± 4.0     |
| Fat mass (kg)    | 34.5 ± 1.9    | 33.5 ± 2.2     |
| Lean mass (kg)   | 58.8 ± 1.9    | 57.6 ± 4.9     |
| HOMA-IR          | 8.0 ± 2.0     | 6.3 ± 1.0*     |
| Fasting plasma biochemistry | | |
| Glucose (mmol/L) | 6.4 ± 0.6     | 6.1 ± 0.6      |
| Insulin (mU/L)   | 27 ± 5        | 23 ± 3         |
| Lactate (mmol/L) | 0.82 ± 0.07   | 1.04 ± 0.08**  |
| Total cholesterol (mmol/L) | 4.5 ± 0.2 | 4.4 ± 0.2 |
| HDL cholesterol (mmol/L) | 1.1 ± 0.1 | 1.2 ± 0.2 |
| Non-HDL cholesterol (mmol/L) | 3.4 ± 0.3 | 3.3 ± 0.2 |
| NEFA (µmol/L)    | 630 ± 66      | 604 ± 53       |
| Triglycerides (mmol/L) | 1.7 ± 0.4 | 1.4 ± 0.3* |
| VLDL-TG (µmol/L) | 954 ± 181     | 726 ± 194*     |
| VLDL-ApoB (µmol/L) | 0.09 ± 0.02 | 0.07 ± 0.01   |
| VLDL-TG/VLDL-ApoB molar ratio | 8833 ± 770 | 8300 ± 1068 |
| 3-hydroxybutyrate (µmol/L) | 91 ± 18 | 88 ± 13       |

* $P < 0.05$, ** $P < 0.01$ pre vs post 12 weeks of metformin treatment.

ApoB, apolipoprotein B; IHTG, intrahepatic triglyceride; NEFA, non-esterified fatty acids; TG, triglyceride.
Clinical Study

CJ Green, T Marjot and others

Metformin increases hepatic DNL

European Journal of Endocrinology

186:3 | 371

Figure 2

The effect of metformin treatment on (A) body weight (kg); (B) intrahepatic triglyceride (IHTG) %; (C) plasma glucose; (D) plasma insulin; (E) rate of disappearance (Rd) of glucose; (F) rate of appearance (Ra) of glucose at the end of the respective clamp phases during the two-step hyperinsulinaemic-euglycaemic clamp pre (black circles and black bars) and post (open circles and open bars) 12 weeks metformin treatment. Data are reported as mean ± S.E.M.

Figure 3

The effect of metformin treatment on (A) plasma non-esterified fatty acids (NEFA); (B) the incorporation of [U-13C]-palmitate in plasma NEFA; (C) the rate of appearance (Ra) of plasma (NEFA); (D) plasma triglycerides (TG); (E) the incorporation of [13C]-palmitate in VLDL-TG; (F) proportion of newly synthesised palmitate in VLDL-TG (hepatic de novo lipogenesis); (G) plasma 3-hydroxybutyrate (3OHB); and (H) 13CO2 production at the end of the respective clamp phases during the two-step hyperinsulinaemic-euglycaemic clamp pre (black bars) and post (open bars) 12 weeks metformin treatment. Data are reported as mean ± S.E.M.

the course of the insulin clamp (Fig. 3A). By including an i.v. infusion of [U-13C]-palmitate complexed with human albumin, we were able to assess the effect of metformin treatment on s.c. adipose FA trafficking. We observed no difference in the incorporation of [U-13C]-palmitate into the plasma NEFA pool over the course of the clamp between the pre- and post-metformin measurements (Fig. 3B). Despite no difference in NEFA concentrations, we unexpectedly observed a significant increase in RaNEFA post- compared to pre-metformin treatment (time x treatment P < 0.001), which appeared to be largely driven by a significant (P < 0.01) increase during the basal period post-metformin treatment (Fig. 3C). As the increase in RaNEFA may have been due to a change in insulin sensitivity, we assessed the correlation with plasma insulin concentrations and found no association (r_s = -0.02, P = 0.68) pre-metformin but a significant inverse association (r_s = -0.71, P = 0.022).
post-metformin. We examined the correlation between pre- and post-metformin for RaNEFA and IHTG and found a tendency for an inverse association ($r_s = -0.61, P = 0.06$) but no correlation between RaNEFA and body weight ($r_s = -0.29, P = 0.43$). To determine if the increase in RaNEFA was due to changes in adipose tissue FA trafficking and metabolism, we assessed the expression of relevant genes in s.c. abdominal adipose tissue biopsies taken pre- and post-metformin treatment. Although the expression of genes involved in FA trafficking remained unchanged (Fig. 4A, B, C and D), interleukin 6 (IL6) expression significantly ($P < 0.05$) decreased (from $1.24 \pm 0.17$ to $0.86 \pm 0.05$ normalised mRNA expression $\Delta \Delta CT$) with metformin treatment.

**Plasma and VLDL-TG and hepatic DNL**

Although there was a tendency ($P = 0.06$) for fasting plasma TG concentrations to decrease after metformin treatment (Table 1), we did not observe a treatment effect over the course of the insulin clamp (Fig. 3D). Fasting plasma VLDL-TG significantly decreased ($P < 0.05$) with metformin treatment (Table 1), with no further differences observed over the course of the insulin clamp (data not shown). Although the VLDL-TG/VLDL-ApoB molar ratio in the fasting state (Table 1) and over the course of the insulin clamp (low insulin: $8971 \pm 1104$ vs $8156 \pm 1207$ and high insulin: $8184 \pm 995$ and $7099 \pm 952$ pre- vs post-metformin, respectively) was lower post-metformin treatment compared to pre-metformin treatment, the changes were not significant.

Systemic NEFA can be taken up by the liver and utilised for the synthesis of TG which can then either be secreted in VLDL or stored in cytosolic lipid droplets. We assessed the appearance of $[U^{13}C] $palmitate (from the $[U^{13}C] $palmitate infusion) into VLDL-TG and found the increase over time tended ($P = 0.06$) to be lower with metformin treatment (Fig. 3E); we did not measure VLDL-TG production or clearance rates. Metformin treatment had no effect on either the relative or absolute contribution of systemic NEFA to VLDL-TG (data not shown). Over the course of the insulin clamp, metformin treatment significantly ($P < 0.05$) increased the relative contribution of DNL FA to VLDL-TG (Fig. 3F); however, when expressed in absolute terms, this effect disappeared (data not shown). We found the relative change in hepatic DNL was positively associated with change in IHTG content ($r_s = 0.75, P < 0.05$) while the absolute change was not ($r_s = 0.52, P = 0.13$).

**Hepatic ketogenesis and whole-body FA oxidation**

Metformin treatment had no effect on plasma 3-hydroxybutyrate (3OHB) concentrations either in the fasting state or over the course of the clamp; 3OHB concentrations were suppressed to nadir by the end of the low insulin phase (Fig. 3G). We measured the appearance of $^{13}C$ (from $[U^{13}C] $palmitate) into expired $CO_{2}$ as a marker of whole-body FA oxidation and found no effect of metformin treatment on $^{13}CO_2$ production in the basal, low, or high insulin phases (Fig. 3H).

**Plasma metabolomics**

We had the opportunity to investigate if changes occurred in the plasma metabolome with metformin treatment for 12 weeks. In our preliminary analysis, relatively few changes were identified. In-line with the plasma biochemical data, plasma lactate (IC FC1.19 p0.0199) levels significantly increased (~one-fold higher, $P < 0.05$) after metformin treatment (Fig. 5A). There were significant ($P < 0.05$) decreases in the plasma levels of total monosaccharide (which is not only composed predominantly of glucose but also includes fructose,
Clinical Study

C J Green, T Marjot and others

Metformin increases hepatic DNL

186:3  373

Clinical Study

C J Green, T Marjot and others

Metformin increases hepatic DNL

European Journal of Endocrinology

373

186.3

Discussion

The present study was undertaken to examine the paradoxical observations of metformin treatment improving insulin sensitivity and plasma lipid profiles despite having inconsistent effects on IHTG content. Overall, we found that 12 weeks of metformin treatment resulted in a significant decrease in body weight and markers of insulin resistance. Despite these beneficial changes, we observed no effect on IHTG content or whole-body FA oxidation and a significant increase in the relative contribution of DNL FA to VLDL-TG. Our findings go some way towards explaining some of the observed clinical disconnect with metformin treatment, between the metabolic benefits of weight loss, yet no impact on IHTG.

The most consistent finding from studies in adults is that metformin treatment decreases body weight (27); however, the effect on IHTG is less clear (8). In the present study, body weight decreased by 2.5% with metformin treatment, with no change in IHTG content, which is in-line with previous studies that have utilised 1H-MRS to quantify IHTG (25, 28). It is plausible that the decrease in body weight was not sufficient to induce a change, although others have reported IHTG content to decrease with weight loss between 1.1 and 8.0% after metformin treatment (8).

The discrepancy in findings may, in part, be explained by the methodology utilised to assess IHTG. Despite the lack of change in IHTG, we and others (27) found metformin treatment to decrease markers of insulin resistance in individuals with and without T2D. In contrast to previous observations in non-diabetic participants (29, 30, 31), we did not observe a significant increase in Rd glucose. However, we observed a significant increase in the basal state Ra glucose after metformin treatment, which suggests an increase in EGP. Others have reported EGP to increase in non-diabetic participants after metformin treatment (32); it has been suggested that the mechanism of action of metformin may be dependent on the glycaemic state of the individual (30, 31). Moreover, it is becoming more evident that the mechanism of action of metformin maybe extra-hepatic; it has been speculated that changes in glucose clearance after metformin treatment could represent increased intestinal glucose uptake (31).

We also observed a significant decrease in the amount of insulin required to maintain glucose homeostasis after metformin treatment, which may be the result of metformin increasing insulin clearance, as reported by some (33) but not others (25).

Treatment with metformin has been suggested to increase hepatic glucose uptake in humans (34), which may then be partitioned into glycogen storage, oxidised, galactose, and mannose) and the amino acids citrulline (AAA FC1.69 p0.0021) and ornithine (AAA FC1.16 p0.0184) in plasma post- compared to pre- metformin treatment (Fig. 5B, C and D). Of the three branched chain amino acids, only isoleucine (AAA FC1.10 p0.0012) was significantly \( P < 0.01 \) higher post-metformin treatment (Fig. 5E and F); there was no change in the level of the aromatic amino acid phenylalanine with metformin treatment (Fig. 5G).

Figure 5

The plasma metabolome and the abundance in plasma (A) lactate, (B) monosaccharide, (C) citrulline, (D) ornithine, (E) leucine, (F) isoleucine, (G) valine, and (H) phenylalanine pre (black circles) and post (open circles) 12 weeks metformin treatment. Data are reported as median ± range.
or utilised in the DNL pathway. We observed a significant increase in the relative contribution of DNL FA to VLDL-TG after 12 weeks treatment with metformin. The change in the relative contribution of DNL FAs between pre- and post-metformin treatment was positively associated with the change in IHTG content, suggesting DNL played a role in maintenance of IHTG. It is also plausible IHTG was maintained due to decreased TG export in VLDL. We observed a significant decrease in VLDL-TG concentrations following metformin treatment, along with a non-significant decreases in VLDL-ApoB concentrations (reflecting particle number) and the VLDL-TG/VLDL-ApoB molar ratio (reflecting particle lipidation). These changes may be due to a (subtle) decrease in VLDL secretion, which would contribute to maintenance of IHTG content. Gormsen et al. (35) reported metformin treatment had no effect on VLDL-TG concentrations, the TG/ApoB ratio, or VLDL-TG Ra. It remains unclear if metformin treatment affects the rate of clearance of VLDL-TG in humans. In line with Gormsen et al. (35), we observed no change in whole-body FA oxidation or plasma 3OHB concentrations with metformin treatment. The lack of change in FA oxidation and ketogenesis, in combination with the increase in hepatic DNL may, in part, explain the maintenance of IHTG content, as cellular conditions would be favouring FA esterification (36).

Elevated plasma NEFA are often suggested as underlying cause of NAFLD/insulin resistance. Although we found a significant time and treatment effect of metformin on RaNEFA, in agreement with others (34, 35) we found no notable change in systemic NEFA concentrations. Despite the higher basal RaNEFA, following metformin treatment, maximal suppression was achieved at the low insulin dose. Gormsen et al. (35) have previously reported that metformin treatment had no effect on whole-body FA turnover or hepatic FA uptake, while others have reported metformin treatment to increase plasma NEFA concentrations in patients with T2D but not control participants (30). Based on the significant inverse association we observed between plasma insulin and RaNEFA, it is plausible that adipose tissue became more insulin sensitive after metformin treatment. We have previously found RaNEFA to be higher (per unit of fat mass) in lean insulin-sensitive compared to overweight/obese insulin-resistant males (16). Karpe et al. (37) also reported that lower plasma insulin levels were associated with a higher NEFA release (per unit of fat mass) from s.c. abdominal adipose tissue. As we have previously found the expression of FA trafficking genes to be significantly lower in obese, insulin-resistant compared to lean, insulin-sensitive s.c. adipose tissue (16), we explored whether metformin affected relevant pathways and found no effect on the expression of FA trafficking genes. Others have reported 6 weeks of metformin treatment in older (71 ± 6.4 years), overweight (29 ± 3.6 kg/m²) adults (n = 14) influenced metabolic genes involved in FA pathways in s.c. abdominal adipose tissue (38). As RdNEFA is assumed to equal RaNEFA (39), we cannot exclude the increase in RaNEFA we observed was due to decreased NEFA clearance rather than increased intracellular TG lipolysis.

We found a significant decrease in the expression of adipose tissue IL6 after metformin treatment. Although we did not measure plasma IL6 concentrations, it would be of interest to determine the effects of metformin on adipose tissue macrophage polarisation as this may influence adipose tissue inflammation. Adeskara et al. (40) found that 3 months of treatment with metformin in individuals with T2D significantly decreased plasma IL6 concentrations. We have previously found the release of IL6 to be significantly lower from gluteofemoral compared to abdominal s.c. adipose tissue (41), suggesting changes in plasma IL6 concentrations will be driven by changes in abdominal s.c. adipose tissue metabolism.

In line with others (42, 43), we observed notable decreases in the plasma levels of citrulline and ornithine following metformin treatment. Both amino acids have prominent roles in the urea cycle and nitric oxide biosynthesis (42). It has been suggested that a metformin-induced decrease in these metabolites may reflect reductions in urea biosynthesis, secondary to reductions in gluconeogenesis (44), although the mechanism(s) responsible remain unclear. Elevated levels of branch chain and aromatic amino acids have been positively associated with T2D risk (45). Although we observed an increase in isoleucine levels after metformin treatment, the relevance remains unclear as there was no effect on leucine or valine levels. Gormsen et al. (30) undertook non-targeted metabolomics analysis on plasma collected from patients with T2D and control subjects before and during 3 months of treatment with metformin. They found changes in amino acid, carbohydrate, and FA pathways and commented that the effect of metformin on the plasma metabolome was dependent on the presence of overt diabetes (30). The effects of an acute, single-dose of metformin on the plasma metabolome has been investigated. Rittig et al. (46) reported that 90 min after patients with cirrhosis had taken 1000 mg of metformin, tricarboxylic acid (TCA) cycle intermediates were elevated suggesting increased tissue glycolysis, along with decreased microbiome-derived metabolites linked to benzoate and hippurate metabolism. Others have found significant changes in pathways linked with valine, leucine...
and isoleucine biosynthesis, phenylalanine metabolism, and FA metabolism after healthy males were given 500 mg of metformin (47). Thus, it is plausible that the lack of change in the plasma metabolome observed in our study was due to participants not having overt T2D and they had not consumed metformin within hours of the measurement.

Our study is not without limitations. We studied a small, heterogeneous cohort of individuals with and without T2D, and this most likely explains the variability in response we observed with metformin treatment. Given our small sample size, it is likely our study was underpowered for many of the outcomes measured. As we did not have a placebo or comparator group, we are limited in drawing firm conclusions about whether the effects we have observed here were due solely to metformin treatment. However, despite the heterogeneity within the group, we observed a robust increase in the relative contribution of DNL FA to VLDL-TG and a clear lack of change in whole-body FA oxidation. We used impedance to assess body composition which is reliant on total body water status, and it is therefore possible we have under or overestimated the changes in fat and lean masses. Although we asked participants to maintain their habitual lifestyle and dietary habits, we did not assess or control dietary intakes and it is therefore possible we have under or overestimated the changes in fat and lean masses. Although we asked participants to maintain their habitual lifestyle and dietary habits, we did not assess or control dietary intakes and therefore it is plausible that the upregulation in hepatic DNL is the result of an increased intake of carbohydrate.

There is clear evidence for the clinical benefits of metformin treatment in individuals with T2D and insulin resistance as it notably improves insulin sensitivity and may lower the risk of CVD which is potentially mediated through improved lipid profiles (27), despite having little effect on IHTG content. Although our data suggest that metformin may not have a direct impact on IHTG content and would support existing recommendations that NAFLD alone is not an indication for initiation of treatment (48), this must be carefully balanced against the wider, well-established benefits of metformin. Here we have presented the effect of metformin on multiple processes that govern IHTG accumulation and may help explain some of the variabilities in clinical data that have previously been reported. The data from this study have unravelled the disconnect in the mechanisms of action of metformin whereby it covaries metabolic benefits and weight loss, without improvement in IHTG; these observations are explained, at least in part, through increased hepatic DNL.

### Funding

The study was funded by a Novo Nordisk Postdoctoral Fellowship run in partnership with the University of Oxford (C J G) and a British Heart Foundation Senior Research Fellowship in Basic Science (FS/15/56/31645 awarded to L H).

### Acknowledgements

The authors thank Sarah White and all CRU staff (University of Oxford) for excellent nursing provision; the volunteers from the Oxford Biobank (www.oxfordbiobank.org.uk) for their participation in this recall study.

### References

1. Eslam M, Sanyal AJ, George J & International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology* 2020 158 1999.e1–2014. e1. ([https://doi.org/10.1053/j.gastro.2019.11.312](https://doi.org/10.1053/j.gastro.2019.11.312))

2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, & Wynner M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016 64 73–84. ([https://doi.org/10.1002/hep.28431](https://doi.org/10.1002/hep.28431))

3. Hodson L & Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. *Nature Reviews: Endocrinology* 2019 15 689–700. ([https://doi.org/10.1038/s41574-019-0256-9](https://doi.org/10.1038/s41574-019-0256-9))

4. Zammit VA. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia. *Biochemical Journal* 2013 451 1–12. ([https://doi.org/10.1042/BJ2012689](https://doi.org/10.1042/BJ2012689))

5. McPherson S, Hardy T, Henderson E, Burt AD, Day CP & Anstee QM. Evidence of NAFLD progression from steatosis to fibrosis- steatohepatitis using paired biopsies: implications for prognosis and clinical management. *Journal of Hepatology* 2015 62 1148–1155. ([https://doi.org/10.1016/j.jhep.2014.11.034](https://doi.org/10.1016/j.jhep.2014.11.034))

6. Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ & Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. *American Journal of Physiology: Endocrinology and Metabolism* 2016 311 E730–E740. ([https://doi.org/10.1152/ajpendo.00225.2016](https://doi.org/10.1152/ajpendo.00225.2016))

7. National Institute for Health care and excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management, 2016. ([https://www.nice.org.uk/guidance/ng49](https://www.nice.org.uk/guidance/ng49))

8. Green CJ, Marjot T, Tomlinson JW & Hodson L. Of mice and men: is there a future for metformin in the treatment of hepatic steatosis? *Diabetes, Obesity and Metabolism* 2019 21 749–760. ([https://doi.org/10.1111/dom.13592](https://doi.org/10.1111/dom.13592))

9. Liu E, Wang C, Zhang L, Xu Y, Jiang L, Gu Y, Cao X, Zhao X, Ye J & Li Q. Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. *International Journal of Molecular Medicine* 2014 33 51–58. ([https://doi.org/10.3892/ijmm.2013.1560](https://doi.org/10.3892/ijmm.2013.1560))

10. Mussio G, Cassader M, Rosina F & Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012 55 885–904. ([https://doi.org/10.1007/s00125-011-2446-4](https://doi.org/10.1007/s00125-011-2446-4))

11. Karpe F, Vasan SK, Humphreys SM, Miller J, Cheseeman J, Dennis AL & Neville MJ. Cohort profile: the Oxford biobank. *International Journal of Epidemiology* 2018 47 21–21g. ([https://doi.org/10.1093/ije/dyx132](https://doi.org/10.1093/ije/dyx132))

12. Marjot T, Green CJ, Charlton CA, Cornfield T, Hazlehurst J, Moolla A, White S, Francis J, Neubauer S, Cobbold JF et al. Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. *JGH Open* 2020 4 433–440. ([https://doi.org/10.1002/jghb.3.12274](https://doi.org/10.1002/jghb.3.12274))
13 Baneree R, Pavlides M, Tunncliiffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. *Journal of Hepatology* 2014 60: 69–77. (https://doi.org/10.1016/j.jhep.2013.09.002)

14 Prahalka C, Pavlides M, Baneree R, McNeil CA, Neubauer S, Karpe F & Hodson L. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men. *Journal of Clinical Endocrinology and Metabolism* 2015 100: 4425–4433. (https://doi.org/10.1210/ecl-2015-2649)

15 Steele R. Use of C14-glucose to measure hepatic glucose production following an intravenous glucose load or after injection of insulin. *Metabolism: Clinical and Experimental* 1959 8: 512–519.

16 McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM, Ruge T, Gilbert M, Fielding BA, Frayn KN et al. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? *Diabetes* 2011 60: 47–53. (https://doi.org/10.2337/db10-0867)

17 Neville MJ, Collins JM, Glyn AL, McCarthy MI & Karpe F. Comprehensive human adipose tissue mRNA and microRNA endogenous control selection for quantitative real-time-PCR normalization. *Obesity* 2011 19: 888–892. (https://doi.org/10.1038/oby.2010.257)

18 Hodson L, Bickerton AS, McQuaid SE, Roberts R, Karpe F, Frayn KN & Fielding BA. The contribution of splanchic fatty to VLDL triglyceride is greater in insulin-resistant than insulin-sensitive men and women: studies in the postprandial state. *Diabetes* 2007 56: 2433–2441. (https://doi.org/10.2337/db07-0654)

19 Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AI, Hovorka R & Umpleby AM. Quantitative measurement of 3-O-methyl-D-glucose by gas chromatography-mass spectrometry as a measure of glucose transport in vivo. *Journal of Mass Spectrometry* 1996 31: 961–966. (https://doi.org/10.1002/(SICI)1096-9888(199609)31:9<961::AID-JMS359>3.0.CO;2-H)

20 Hodson L, McQuaid SE, Humphreys SM, Milne R, Fielding BA, Frayn KN & Karpe F. Greater dietary fat oxidation in obese compared with lean men: an adaptive mechanism to prevent liver fat accumulation? *Journal of Applied Physiology* 2010 299: ES84–ES92. (https://doi.org/10.1152/japplphysiol.00790.2016)

21 Kury D & Keller U. Trimethylsilyl-O-methyloxime derivatives for the detection of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells. *Communications Biology* 2020 3: 247. (https://doi.org/10.1038/s42003-019-0291-1)

22 Walsby-Tickle J, Gannon J, Hviinden I, Bardella C, Aboud MI, Nazerz A, Hauton D, Pies C, Cadoux-Hudson T, Schofield CJ et al. Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells. *Communications Biology* 2020 3: 247. (https://doi.org/10.1038/s42003-020-0975-6)

23 Inzucchi SE, Maggs DG, Splolitt GR, Page SL, Rife FS, Walton V & Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. *New England Journal of Medicine* 1999 338: 867–872. (https://doi.org/10.1056/NEJM199903263381303)

24 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheiman AO, Sanyal AJ, Chalasani N et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011 305: 1659–1668. (https://doi.org/10.1001/jama.2011.520)

25 Tilkikainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimatlila S & Kii-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. *Diabetes* 2004 53: 2169–2176. (https://doi.org/10.2337/ diabetes.53.8.2169)

26 Chong J, Wishart DS & Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. *Current Protocols in Bioinformatics* 2019 68: e86. (https://doi.org/10.1002/cpbl.86)

27 Salpeter SR, Buckley NS, Kahn JA & Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. *American Journal of Medicine* 2008 121: 149.e2–157.e2. (https://doi.org/10.1016/j.amjmed.2007.09.016)

28 Loomba R, Lutlman G, Kleiner DE, Ricks M, Feld J, Borg BB, Modo A, Nagabiyru F, Sunner AE, Liang TJ et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. *Alimentary Pharmacology and Therapeutics* 2009 29: 172–182. (https://doi.org/10.1111/j.1365-2036.2008.03869.x)

29 Christensen MS, Holjund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H & Brosen K. Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. *Diabetologia* 2015 58: 2494–2502. (https://doi.org/10.1007/s00125-015-3733-2)

30 Gormsen LC, Sondergaard EA, Christensen NL, Brosen K, Jensen N & Nielsen S. Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. *Diabetologia* 2019 62: 1251–1256. (https://doi.org/10.1007/s00125-019-4872-7)

31 McCreight LJ, Mari A, Coppin L, Jackson N, Umpleby AM & Pearson ER. Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. *Diabetologia* 2020 63: 444–447. (https://doi.org/10.1007/s00125-019-05042-1)

32 Sundelin E, Jensen JB, Jakobsen S, Gormsen LC & Jessen N. Metformin biodistribution: a key to mechanisms of action? *Journal of Clinical Endocrinology and Metabolism* 2020 105. (https://doi.org/10.1210/clinem/dgaa332)

33 Viscohil R, Malin SK, Blankenship JM & Braun B. Exercise training and metformin, but not exercise training alone, decreases insulin production and increases insulin clearance in adults with prediabetes. *Journal of Applied Physiology* 2017 123: 243–248. (https://doi.org/10.1152/japplphysiol.00790.2016)

34 Iozzo F, Hallstein K, Oikonen V, Virtanen KA, Parkkola R, Kemppainen J, Solin O, Lonnqvist F, Ferrannini E, Knuuti J et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. *Diabetes Care* 2003 26: 2069–2074. (https://doi.org/10.2337/diacare.26.7.2069)

35 Gormsen LC, Sondergaard EA, Christensen NL, Jakobsen S, Nielsen EHT, Munk OI, Tolbod LP, Jessen N & Nielsen S. Metformin does not affect postsorptive hepatic free fatty acid uptake, oxidation or resecretion in humans: a 3-month placebo-controlled clinical trial in patients with type 2 diabetes and healthy controls. *Diabetes, Obesity and Metabolism* 2018 20: 1435–1444. (https://doi.org/10.1111/dob.13244)

36 McGarry JD, Mannaaerts GP & Foster DW. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. *Journal of Clinical Investigation* 1977 60: 243–248. (https://doi.org/10.1172/JCI108764)

37 Karpe F, Dickmann JR & Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. *Diabetes* 2011 60: 2441–2449. (https://doi.org/10.2337/db11-0425)

38 Kulikarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden Z, Pollak M, Mar JC, Hawkins M, Crandall JP & Barzilai N. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. *Aging Cell* 2017 16: 1435–1444. (https://doi.org/10.1111/acel.12723)

39 Sarac I, Backhouse K, Shojaee-Moradie F, Stolinski M, Robertson MD, Bell JD, Thomas EL, Hovorka R, Wright J & Umpleby AM. Gender differences in VLDL1 and VLDL2 triglyceride kinetics and fatty acid kinetics in obese postmenopausal women and obese men. *Journal of
Clinical Study

C J Green, T Marjot and others

Metformin increases hepatic DNL

186:3 | 377

European Journal of Endocrinology

Clinical Endocrinology and Metabolism 2012 97 2475–2481. (https://doi.org/10.1210/jc.2011-3248)

40 Adeshara KA, Bangar NS, Doshi PR, Diwan A & Tupe RS. Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study. Diabetes and Metabolic Syndrome 2020 14 1449–1458. (https://doi.org/10.1016/j.dsx.2020.07.036)

41 Pinnick KE, Nicholson KN, Manolopoulos KN, McQuaid SE, Valet P, Fray KN, Denton N, Min JL, Zondervan KT, Fleckner J et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014 63 3785–3797. (https://doi.org/10.2337/db14-0385)

42 Irving BA & Spielmann G. Does citrulline sit at the nexus of metformin’s pleotropic effects on metabolism and mediate its salutary effects in individuals with type 2 diabetes? Diabetes 2016 65 3537–3540. (https://doi.org/10.2337/db16-0050)

43 Konopka AR, Esponda RR, Robinson MM, Johnson ML, Carter RE, Schiavon M, Cobelli C, Wondisford FE, Lanza IR & Nair KS. Hyperglucagonemia mitigates the effect of metformin on glucose production in prediabetes. Cell Reports 2016 15 1394–1400. (https://doi.org/10.1016/j.celrep.2016.04.024)

44 Irving BA, Carter RE, Soop M, Weymiller A, Syed H, Karakelides H, Bhagra S, Short KR, Tatpati L, Barazzoni R et al. Effect of insulin sensitizer therapy on amino acids and their metabolites. Metabolism: Clinical and Experimental 2015 64 720–728. (https://doi.org/10.1016/j.metabol.2015.01.008)

45 Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP; McCabe E, Lewis GD, Fox CS, Jacques PF; Fernandez C et al. Metabolite profiles and the risk of developing diabetes. Nature Medicine 2011 17 448–453. (https://doi.org/10.1038/nm.2307)

46 Rittig N, Aagaard NK, Sundelin E, Villadsen GE, Sandahl TD, Holst JJ, Hartmann B, Brous K, Gronbaek H & Jessen N. Metformin stimulates intestinal glycolysis and lactate release: a single-dose study of metformin in patients with intrahepatic portosystemic stent. Clinical Pharmacology and Therapeutics 2021 110 1329–1336. (https://doi.org/10.1002/cpt.2382)

47 Dahabiyeh LA, Mujammami M, Arafat T, Benabdellamek H, Al-Fadda AA & Abdel Rahman AM. A metabolic pattern in healthy subjects given a single dose of metformin: a metabolomics approach. Frontiers in Pharmacology 2021 12 705932. (https://doi.org/10.3389/fphar.2021.705932)

48 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM & Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology 2018 67 328–357. (https://doi.org/10.1002/hep.29367)

Received 17 August 2021
Revised version received 9 January 2022
Accepted 17 January 2022